ICU Medical Reports Q3 2026 Growth Driven by Infusion Systems and Consumables
ICU Medical (ICUI) reported strong third-quarter results for fiscal year 2026, highlighted by a 4% increase in total GAAP revenue to $560.4 million. The company saw significant momentum in its core segments, with consumables reaching record sales of $298.4 million and infusion systems growing 11% due to high demand for large volume pumps. Despite these gains, the Vital Care segment experienced a 12% decline in revenue caused by international logistics consolidation challenges. However, management successfully improved adjusted gross margins to 42% and utilized healthy cash flows to repay $80 million in debt. The company's year-to-date free cash flow of $172.7 million has already surpassed its full-year target. Looking ahead, ICU Medical provided optimistic full-year guidance for Adjusted EBITDA ($415M–$435M) and Adjusted EPS ($8.60–$9.00), with management expecting to hit the higher end of these ranges. Potential headwinds include foreign currency fluctuations and uncertainty regarding future Section 232 tariffs.
Tickers: $AAPL $AMZN $GOOG $ICUI $META $MSFT $NVDA $TSLA
Topics: adjusted eps debt repayment free cash flow margin expansion revenue growth
Read the full article at Motley Fool
Part of the story Kelly Services Projects Q4 Adjusted EBITDA Margin Between 3.8% and 4% (21 articles)